AI in Life-Sciences

Artificial intelligence is transforming life sciences in the UK, enabling faster decision making, improved data analysis and greater operational efficiency across regulated environments. From automating complex processes to enhancing scientific and quality outcomes, AI offers significant opportunities to improve both effectiveness and performance.

However, in GxP regulated settings, AI adoption must go beyond innovation. It requires structured governance, clear policy frameworks and a risk based approach to validation to ensure full AI compliance with regulatory expectations. Without this, organisations risk compliance gaps, data integrity issues and increased regulatory scrutiny.

At IS Compliance Solutions, we support organisations in implementing AI in life sciences in a controlled, compliant and scalable way. Our approach aligns AI initiatives with GxP requirements, regulatory guidance and business objectives, ensuring solutions are both effective and audit ready.

We focus on embedding AI within existing quality management systems, supporting validation, data integrity and lifecycle control. This ensures AI solutions deliver measurable efficiency gains while remaining fully compliant, transparent and inspection ready across the organisation.

MHRA

Expectation is that AI systems used in the development, manufacture or monitoring of medicines and medical devices to comply with existing GxP standards.

USA FDA

The FDA has made clear that AI/ML-based systems, including Software as a Medical Device (SaMD), are subject to the same regulatory controls as other medical technologies.

EU EMA

Edit your Features from the Pages tab bThe European Medicines Agency expects AI to operate within established GxP frameworks, including GMP, GVP and GCP.y clicking the edit button.

EU

The EU AI Act introduces a risk-based framework for AI systems, with many life sciences applications likely to be classified as high-risk.

Accountability

AI systems are not recognised as decision-makers. Responsibility for outcomes remains fully with the regulated entity.

Data Integrity

Inputs, transformations, and outputs generated by AI systems must remain attributable, traceable, and reviewable.

Validation

AI does not sit outside established validation principles. However, defining appropriate validation approaches for adaptive or non-deterministic systems presents new challenges.

Human in the Loop

Regulators continue to expect meaningful human control over GxP-relevant decisions.

AI Governance, Policy and Compliance Frameworks

Artificial intelligence must be governed with the same discipline as any other regulated system. Without clear policy and structured oversight, organisations risk inconsistency, operational risk and regulatory exposure. We support the development of robust AI governance frameworks aligned with GxP requirements, ensuring AI is fully integrated into existing quality systems, with clear accountability, control and lifecycle oversight.

Building a Robust and Defensible AI Business Case

Successful AI adoption begins with a clear and defensible business case. In regulated environments, this must balance innovation with risk, compliance and long term sustainability. We help organisations identify appropriate use cases, assess impact and risk, and build evidence based justifications that support informed decision making and ensure AI initiatives are both valuable and audit ready.

Risk Based AI Validation and Assurance

Validation remains a fundamental requirement in regulated environments, and AI introduces additional complexity that must be managed effectively. We apply a risk based approach to AI validation, ensuring systems are controlled in line with their intended use and impact. Our approach aligns with CSV and CSA principles, supporting audit readiness and ongoing lifecycle assurance.

AI in Life-Sciences

Regulatory Expectations